Current therapeutic developments in atrophic age-related macular degeneration

Jakub Hanus,1 Fangkun Zhao,1,2 Shusheng Wang1,3

ABSTRACT

Age-related macular degeneration (AMD), a degenerative disorder of the central retina, is the leading cause of irreversible blindness in the elderly. The underlying mechanism of the advanced form of dry AMD, also named geographic atrophy (GA) or atrophic AMD, remains unclear. Consequently, no cure is available for dry AMD or GA. The only prevention option currently available is the Age-Related Eye Disease Study (AREDS) formulation, which has been demonstrated to slow down the progression of dry AMD. This review summarises recent advances in therapy for dry AMD and GA. Building on the new understanding of the disease and recent technological breakthroughs, numerous ongoing clinical trials have the goal of meeting the need to cure AMD. Therapeutic agents are being developed to target the key features of the disease, including inhibiting the complement pathway and other inflammatory pathways, reducing oxidative stress and protecting retinal pigment epithelial (RPE) cells, inhibiting lipofuscin and visual cycle, regenerating RPE cells from stem cells and restoring choroidal blood flow. Some of these therapeutic options, especially the stem cell-based therapy, hold great promise, which brings great hope for this devastating blinding disease.

INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in the developed world. About 8.7% of the world’s population has AMD, and the number is projected to increase to approximately 196 million in 2020 and to approximately 288 million in 2040.1 The direct cost associated with AMD globally is estimated at $2.55 billion.2 AMD is characterised by drusen and pigment changes in the choroid/retinal pigment epithelial (RPE) layers in the macula, the region of central retina responsible for fine visual acuity.3 4 The advanced stage of AMD has dry and neovascular (wet) forms, with no exclusive dichotomy between them. The advanced form of dry AMD is called geographic atrophy (GA) or atrophic AMD. GA is characterised by well-defined areas of RPE loss followed by the degeneration of the corresponding photoreceptors and thinning of the retina.5 Neovascular AMD is characterised by choroidal neovascularisation (CNV). Severe central visual impairment or blindness can develop as a result of neovascular or dry AMD. Dry AMD accounts for 85%–90% of cases of AMD, and GA is responsible for approximately 20% of all cases of legal blindness.6 Considerable amelioration of neovascular AMD can be achieved with the use of antiangiogenic agents, photodynamic therapy or thermal laser.7–9 However, no cure is currently available for dry AMD, and the only preventive option is the Age-Related Eye Disease Study (AREDS) formulations, which reduce the risk of AMD progression by 25%–30% over a 5-year period.10 11

The etiology of AMD and GA remains elusive, and is believed to result from a combination of factors, including sustained oxidative stress, chronic inflammation, predisposing genetic and environmental factors.12 13 Intensive oxygen metabolism, continual exposure to light, high concentrations of polyunsaturated fatty acids, and the presence of photosensitizers increase the production of reactive oxygen species (ROS) in the retina. ROS-induced oxidative stress can cause the induction of programmed necrosis in RPE cells and chronic inflammation, leading to a pathological immune response in AMD (figure 1).14 Consistently, knockout of antioxidative genes in mice (Sod1−/− mice, Sod2 knockout mice and Nr2f2−/− mice) results in the development of the typical features of AMD.15 16 Genetically, polymorphism in a number of genes, including members of the complement pathway, apolipoprotein E (ApoE), ARMS2, HTRA1, CX3CR1, VEGF-A and ABCA4 have been associated with AMD, indicating the involvement of inflammation, lipid metabolism, RPE dysfunction, and angiogenesis in AMD.17

Built on a new understanding of the genetics and pathogenesis of AMD, as well as new breakthroughs in stem cell biology, numerous efforts have been focused on developing novel therapy for dry AMD and GA. This review focuses on recent or ongoing clinical trials (summarised in table 1), dividing therapeutic agents into five categories: anti-inflammatory agents, antioxidation and RPE protection agents, lipofuscin and visual cycle inhibitors, choroidal blood flow restoration agents, and stem cell-based therapy. If you are interested in other potential future therapeutics not yet in clinical trials, refer to the recent review by Cunnusamy et al.18

CURRENT THERAPEUTIC DEVELOPMENTS FOR GA

Anti-inflammatory agents

Chronic inflammation is believed to play an important role in AMD pathogenesis.19 Extracellular drusen deposits, located between the RPE and Bruch’s membrane, contain RPE debris (including apolipoprotein E) and inflammatory proteins, such as complement components and complement activators. This suggests the involvement of inflammation in early pathogenesis of AMD.20 Drusen accumulation together with oxidative stress can result in RPE cell damage or death, leading to...
sustained inflammatory response resulting in the progression of AMD. Polymorphisms in the complement pathway, including complement factors H, B and I, and complement components 2, 3, and 7 have been shown to be associated with AMD. Activation of the membrane pathway leads to the formation of the membrane attack complex that causes target cell lysis and chemokine release, which in turn can recruit inflammatory cells and increase vascular permeability. Inhibition of the overactive complement pathway and other inflammatory pathways represents a viable therapeutic approach for halting AMD and GA.

Eculizumab is the first Food and Drug Administration (FDA)-approved complement inhibitor for the treatment of uveitic syndrome. It is a humanised IgG antibody that inhibits C5 activation. The Complement Inhibition with Eculizumab for the Treatment of Nonexudative Age-Related Macular Degeneration (COMPLETE) phase II trial on eculizumab recruited 60 participants (50 years and older) with dry AMD documented by fundus photography, fundus autofluorescence (FAF) and fluorescein angiography. The first group of patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg for every 2 weeks until week 24. The second group of patients received a high-dose regimen of 900 mg followed by 1200 mg over the same time frame. Primary outcome measured change in drusen volume and GA area at 26 weeks. The study showed that systemic complement inhibition with eculizumab was well tolerated through 6 months, but did not decrease the growth rate of GA or drusen significantly.

Lampalizumab is a humanised monoclonal antibody targeting complement factor D in the alternative complement pathway. In a phase II trial, lampalizumab showed a reduction rate of 20.4% in the GA area at 18 months in patients with advance dry AMD. Phase III study is currently recruiting participants with estimated enrolment of 936 participants at age 50 years and older. Participants will receive a high-dose regimen of lampalizumab administered intravitreally. Primary outcomes will measure change in GA area after 48 weeks, and best corrected visual acuity (BCVA) up to 2 years after the beginning of the study.

Table 1 Summary of clinical trials targeting geographic atrophy

<table>
<thead>
<tr>
<th>Target</th>
<th>Treatment</th>
<th>Clinical trial number</th>
<th>Company</th>
<th>Status of clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-inflammatory</td>
<td>Eculizumab</td>
<td>NCT00935883</td>
<td>Alexion Pharmaceuticals (Cheshire, Connecticut, USA)</td>
<td>Completed phase II</td>
</tr>
<tr>
<td></td>
<td>Sirolimus</td>
<td>NCT00766649</td>
<td>National Eye Institute (Baltimore, Maryland, USA)</td>
<td>Completed phase II</td>
</tr>
<tr>
<td></td>
<td>Lampalizumab</td>
<td>NCT02247479</td>
<td>Hoffmann-LaRoche (Basel, Switzerland)</td>
<td>Phase III currently recruiting</td>
</tr>
<tr>
<td></td>
<td>ARC-1905</td>
<td>NCT00950638</td>
<td>Ophthotech (Princeton, New Jersey, USA)</td>
<td>Completed phase I</td>
</tr>
<tr>
<td></td>
<td>Glatiramer acetate</td>
<td>NCT00541333</td>
<td>The New York Eye &amp; Ear Infirmary (New York, New York, USA)</td>
<td>Phase I suspended participant recruitment</td>
</tr>
<tr>
<td>Antioxidants</td>
<td>AREDS2</td>
<td>NCT00345176</td>
<td>National Eye Institute (Baltimore, Maryland, USA)</td>
<td>Phase III completed</td>
</tr>
<tr>
<td></td>
<td>OT-551</td>
<td>NCT00306488</td>
<td>National Eye Institute (Baltimore, Maryland, USA)</td>
<td>Phase II completed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other Pharmaceuticals (Exton, Pennsylvania, USA)</td>
<td></td>
</tr>
<tr>
<td>Visual cycle</td>
<td>Fenioretinide</td>
<td>NCT00429936</td>
<td>Sirion Therapeutics, Inc. (Tampa, Florida, USA)</td>
<td>Phase II completed</td>
</tr>
<tr>
<td>inhibitors</td>
<td>Emixustat Hydrochloride (ACU-4429)</td>
<td>NCT01802866</td>
<td>Accube Inc. (Seattle, Washington, USA)</td>
<td>Phase III ongoing</td>
</tr>
<tr>
<td></td>
<td>ALX-001</td>
<td>NCT02230228</td>
<td>Alkeus Pharmaceuticals, Inc. (Boston, Massachusetts, USA)</td>
<td>Phase I completed</td>
</tr>
<tr>
<td>Amyloid beta</td>
<td>MRZ-99030</td>
<td>NCT01714960</td>
<td>Merz Pharmaceuticals GmbH (Dessau-Roßlau, Germany)</td>
<td>Phase I completed</td>
</tr>
<tr>
<td></td>
<td>R66G</td>
<td>NCT01003691</td>
<td>Pfizer (New York, New York, USA)</td>
<td>Phase I completed</td>
</tr>
<tr>
<td></td>
<td>GSX-033776</td>
<td>NCT01342926</td>
<td>GlaxoSmithKline (Brentford, UK)</td>
<td>Phase II ongoing</td>
</tr>
<tr>
<td>Choroidal perfusion</td>
<td>MC-1101</td>
<td>NCT02127463</td>
<td>MacuCLEAR, Inc. (Plano, Texas, USA)</td>
<td>Phase III currently recruiting</td>
</tr>
<tr>
<td>Stem cell therapy</td>
<td>MA09-IRPE</td>
<td>NCT01340493</td>
<td>Ocuta Therapeutics (Marlborough, Massachusetts, USA)</td>
<td>Phase III currently recruiting</td>
</tr>
<tr>
<td></td>
<td>MA09-IRPE</td>
<td>NCT01674829</td>
<td>CHABiotech Co., Ltd (Seoul, South Korea)</td>
<td>Phase III currently recruiting</td>
</tr>
<tr>
<td></td>
<td>HuCNS-SC</td>
<td>NCT01632527</td>
<td>StemCells, Inc. (Newark, California, USA)</td>
<td>Phase III ongoing</td>
</tr>
</tbody>
</table>

AREDS2, Age Related Eye Disease Study 2; hRPE, retinal pigment epithelial; HuCNS-SC, human central nervous system stem cells.
renal transplantation and coronary artery restenosis following balloon angioplasty. It functions by inhibiting the mechanistic target of rapamycin (mTOR) pathway, which can regulate diverse processes, such as cell growth, survival and autophagy. Phase III study recruited 11 participants aged 55 years and older to evaluate the safety of sirolimus in patients with GA and if it can help preserve vision in patients. The participants received 440 μg subconjunctival injections of sirolimus in the study eye at baseline and every 3 months thereafter. The rate of change in area of GA was evaluated by fundus photography at 24 months and compared with baseline. This clinical study showed that sirolimus injections did not decrease the rate of GA area growth.

Copaxone (or glatiramer acetate) functions to induce suppressor T cells and downregulates inflammatory cytokines. A phase I trial was designed to test its safety and efficacy in the prevention of GA progression or conversion of dry AMD to neovascular AMD. The recruitment of participants has been suspended with no results posted yet.

**Antioxidation and RPE protection agents**

Oxidative stress has been suggested to be a critical component of AMD pathogenesis. Oxidative stress can lead to the damage and degeneration of the RPE layer, which is crucial for maintaining the homeostasis of the retina. In support of a critical role for oxidative stress in AMD, cigarette smoking, which induces systemic oxidative stress, is a proven risk factor for AMD. Modified oxidative products, such as carboxyethylpyrrole and malondialdehyde, have been shown to cause inflammatory response and retinal phenotypes in animal models similar to that in AMD. Amyloid-β, major proinflammatory component of the plaques in Alzheimer’s disease, was also observed in drusen and was correlated with the location of degenerating photoreceptors and RPE cells. On account of these findings, antioxidants and amyloid-β inhibitors have been tested in clinical trials for preventing AMD and GA progression.

The previous phase III AREDS trial has shown that nutritional supplements, which contain vitamin C, vitamin E, β-carotene, zinc and copper, reduced progression to advanced neovascular AMD by 25% over the 5-year study period with no effect on AMD progression to GA. The AREDS2 trial was designed to test whether adding lutein and zeaxanthin (or substituting them for β-carotene) and/or omega-3 fatty acids could improve the AREDS formulation. This large-scale trial enrolled more than 4000 participants, aged 50–85 years, at risk for advanced AMD. The primary outcome was to determine the development of advanced AMD in people at moderate to high risk of progression. The study found that lutein and zeaxanthin together appeared to be safe and effective alternative to β-carotene in a median follow-up period of 5 years (IQR, 4.3–5.1 years). Analyses of the AREDS participants over a 12-year period found that participants with the highest omega-3 fatty acids intake were 30% less likely than their peers to develop central GA and neovascular AMD. OT-551 (disubstituted hydroxylamine) is a small molecule with antioxidant and anti-inflammatory properties. It has been shown to protect light-induced RPE degeneration in vivo.

A phase II study has been performed on a small group of 11 participants, aged 60 years and older, with GA present in both eyes. Topical OT-551 (at 0.45%) eye drops were given three times a day for up to 3 years. The primary and secondary outcomes included measuring BCVA and fundus autofluorescence (FAF), respectively. The study showed that topical administration of OT-551 was well tolerated but did not exert a significant effect on lesion enlargement, retinal sensitivity or total drusen area.

Currently, there are three clinical trials targeting amyloid-β to treat AMD. MRZ-99030, developed as eye drops, is a dipeptide containing d-tryptophan and 2-amino-2-methylpropionic acid designed to modulate aggregation of amyloid-β. RN6G is a humanised antibody to prevent accumulation of amyloid β-40 and β-42 and is delivered by intravenous injections. Both treatments completed phase I studies to assess their safety and tolerability. GS933776 is a humanised monoclonal antibody intended to modulate levels of amyloid-β. A Phase II trial to investigate the safety and efficacy of GS933776 in patients with GA secondary to AMD is currently ongoing. One hundred and eighty-four patients with GA aged 55 years and older will receive 3, 6 or 15 mg/kg of GS933776 via intravenous infusion. The primary outcome is to measure the rate of change in GA area from baseline to 12 and 18 months. The secondary outcome is the change in BCVA from baseline to 18 months.

**Lipofuscin and visual cycle inhibitors**

Accumulation of lipofuscin and melanolipofuscin granules have been observed at the sites of RPE atrophy in GA eyes and associated with the GA pathogenesis. Lipofuscin consists of products of peroxidation-derived protein modifications and the advanced glycation end products. Oxygen uptake in lipofuscin leads to formation of singlet oxygen, superoxide anion and hydrogen peroixide. A2E, derived from vitamin E, is a byproduct of the visual cycle and a component of lipofuscin. A2E was shown to be phototoxic to RPE cells in vitro. Oxysterols are generated as byproducts of visual cycle by peroxidation of cholesterol, steroid and fatty acids, and metabolised predominantly in RPE cells. Excess accumulation of oxysterols in the lipofuscin pockets or in Bruch’s membrane leads to RPE and photoreceptor cell death. It also acts as an attractant for macrophages to induce inflammation. Because of documented lipofuscin phototoxicity, targeting lipofuscin and the visual cycle has been proposed as an approach for treating AMD.

Fenretinide (RT-101) was shown to effectively block the formation of A2E and other lipofuscin fluorophores in vivo, with no deleterious effects on visual function or retinal morphology. It functions to reduce the circulating levels of retinol and its carrier protein, the retinol binding protein. A Phase II study has been performed to determine the efficacy of fenretinide in GA treatment in 245 patients with GA (50–89 years old). The patients received one 100 mg fenretinide softgel capsule per day for 24 months. No significant trend in reducing GA lesion growth rate was observed over the 24-month period.

Emixustat is a nonretinoid compound that directly modulates the biosynthesis of visual chromophores through inhibition of RPE-specific protein isomerase 65 (RPE65). RPE65 converts all-trans retinal to 11-cis retinal so it can re-enter the visual cycle. Emixustat also binds to RAR/RXR retinoid receptors or antagonise retinoid-binding proteins. Phase II/III clinical trial is ongoing to determine whether orally delivered emixustat hydrochloride (ACU-4429) reduces the rate of GA progression by measuring GA area and BCVA in 480 recruited patients (55 years and older) in a 24-month period.

ALK-001 is a modified form of vitamin A, in which three ordinary hydrogen atoms have been replaced by nonradioactive, heavy hydrogen atoms. The changes embodied in the ALK-001 molecule make it more difficult to form toxic vitamin A dimer (P2E), a byproduct of vitamin A recycling process contributing to lipofuscin formation in RPE cells. In vitro results showed that ALK-001 caused approximately sevenfold decrease in the formation of toxic vitamin A aggregates. A Phase I study was designed to assess the safety and
pharmacokinetics of oral ALK-001 capsules in 40 healthy volunteers (21–70 years old) with no results posted yet.

**Choroidal blood flow restoration agents**

Choroidal circulation provides the nutrition and removes the wastes from the retina/RPE. As a consequence of a reduced choroidal blood flow, metabolic wastes accumulate in the photoreceptor cells, Bruch’s membrane and RPE cells. Those events can lead to the development of GA. Therefore, improving choroidal blood flow could facilitate the removal of metabolic wastes from RPE, Bruch’s membrane and photoreceptor cells to halt AMD disease progression.

MC-1101 is an FDA-approved oral antihypertensive drug. Its active substance, hydralazine, has been shown to increase choroidal blood flow in ocular hypertensive rabbit models and facilitate retinal function recovery following ischaemic insult in rat eyes. It also prevents the rupture of the Bruch’s membrane and has anti-inflammatory and antioxidative properties. Phase Ib clinical trial showed that topical instillation of 1% MC-1101 produced no significant cardiovascular effects or ocular toxicity; no effect on the blood–eye barrier was noted. Phase II/III is ongoing, and 60 patients (50–85 years old, with early to intermediate dry AMD) will receive topical 1% ophthalmic solution and be assessed for visual function over 24 months.

**Stem cell therapy**

Stem cell-based therapy provides new hope for people at risk or suffering from blindness due to degenerative retinal diseases. Replenishing the lost or degenerating RPE cells in GA before the photoreceptors are irrevocably damaged with stem cell-derived RPE cells represents the forefront in the practice of regenerative medicine. RPE can be differentiated from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (iPSCs) hESC or human iPSC-derived RPE cells display RPE-like morphology and express typical RPE markers and have the ability to phagocytose photoreceptor segments. When they were transplanted subretinally into rat or mouse model of RPE dysfunction, the grafted cells were retained and retinal function improved.

Based on the preclinical data, the first clinical trials investigating the subretinal transplantation of hESC-derived RPE cells have been approved by European and American regulatory authorities. Phase I trials were designed to test the safety and tolerability of grafted hESC-derived RPE cells in patients with either dry AMD or Stargardt’s macular dystrophy. The data showed that transplanted cells persisted at 4 months after transplantation with no signs of rejection or evidence of hyperproliferation or tumourigenesis. In addition, functional recovery was observed in patients receiving hESC-derived RPE. Based on these, two phase I/II trials were performed with 18 patients enrolled. The patients received subretinal injections of 50 000–150 000 RPE cells and followed up for a median of 22 months (12–36 months). Results showed BCVA improvement compared with non-injected fellow eyes, also vision-related quality-of-life had improved in patients with atrophic AMD and Stargardt’s disease. This study provided the first evidence of the medium- to long-term safety, survival and biological activity of the stem cell-derived cells in human disease.

There are currently two other clinical trials using hESC-RPE cells (MA09-hRPE). Both are designed to evaluate safety and tolerability of subretinal injection or transplantation of MA09-RPE cells in patients with dry AMD. Both studies are recruiting patients aged 55 years and older, who will receive 50 000–200 000 MA09-hRPE cells. The primary outcome of both studies is to evaluate the safety of hESC-derived RPE cells. Secondary outcomes will measure the mean change of BCVA, autofluorescence photography and reading speed.

In a separate study, clonogenic human central nervous system stem cells (HuCNS-SC) will be evaluated for treatment of dry AMD. In vivo studies in rats showed that transplantation of the HuCNS-SC cells preserve the number of photoreceptors and thereby visual function in rodent model of retina degeneration. Phase I/II study will investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with GA secondary to AMD.

**CONCLUSIONS AND FUTURE DIRECTIONS**

GA is a devastating blinding disease without any cure currently available. However, numerous clinical trials are ongoing with the goal of finding a viable solution to prevent or treat the disease. These therapies target different aspects of GA, including inflammatory pathways, oxidative stress and RPE degeneration, byproducts of the visual cycle, restoration of choroidal perfusion, and replenishing RPE cells with stem cell-derived RPE cells. Some of the trials hold great promise. The AREDS trials show that AREDS formulation reduces the risk of AMD progression by 25%–30%, whereas transplanted hESC-derived RPE cells show medium-term and long-term safety, graft survival and possible biological activity shown by improved vision acuity in patients with GA.

Future studies should focus on understanding the pathogenesis of the disease, which remains unclear. The precise delineation of pathological processes within the retina is especially valuable to gain insight of AMD, thus, the correlation between function and morphology play a pivotal role in diagnosing the disease. Clinical studies use FAF imaging to evaluate progressive enlargement of GA. FAF is based on the optical properties of lipofuscin and photoreceptor degeneration products and allows observing lesion areas. The development of advanced imaging system provides state-of-art tools for analysing GA pathophysiology and testing new therapeutics. In this regard, the recent development of spectral domain optical coherence tomography (SD-OCT) and polarisation-sensitive OCT (PS-OCT) technologies allows high-resolution structural imaging of the retinal and subretinal layers, providing powerful methods to quantify GA lesion size and grade GA progression. These new insights in GA morphology using novel retinal imaging strategies are important to design new studies appropriately.

For therapeutic research, it would be critical to test the long-term safety and efficacy of the current hESC- or iPSC-based RPE transplantation approach for GA. Other approaches, including innovative approaches to prevent RPE degeneration, should also be explored. Learning from the clinical trials, going from bedside to the benchside, then back to the bedside could lead to better understanding of the AMD mechanism and better therapy for the disease.

**Acknowledgements**

The authors thank Chastain Anderson for proofreading the manuscript.

**Contributors**

Jakub Hanus wrote and edited the manuscript. Fangkun Zhao wrote the manuscript. Shusheng Wang wrote and edited the manuscript.

**Funding**

US Department of Health and Human Services > National Institutes of Health > National Eye Institute: EY021862. Startup fund from Tulane University. Career development award from the Research to Prevent Blindness foundation and Bright Focus Foundation Award in Age-related Macular Degeneration.

**Competing interests**

None declared.

**Provenance and peer review**

Not commissioned; externally peer reviewed.


Kokkinaki M, Sahibzada N, Golestaneh N. Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE. *Stem Cells* 2011;29:825–35.


Correction: Current therapeutic developments in atrophic age-related macular degeneration

Hanus J, Zhao F, Wang S. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol 2016;100:122–7. In the first paragraph of the “Lipofuscin and visual cycle inhibitors” section of the paper (p. 124), the authors state “A2E, derived from vitamin E, is a byproduct of the visual cycle and a component of lipofuscin”. This sentence should read: “A2E, derived from vitamin A, is a byproduct of the visual cycle and a component of lipofuscin”.